On March 5, 2024 Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, reported that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, being held April 5-10 in San Diego, California (Press release, Elevation Oncology, MAR 5, 2024, View Source [SID1234640816]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to share preclinical proof-of-concept data for our HER3-ADC program. HER3 is a clinically validated oncology and ADC target, which is overexpressed across a range of solid tumors, and is often associated with a poor clinical outcome," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "At AACR (Free AACR Whitepaper), we plan to share preclinical proof-of-concept data highlighting our progress towards the development of a differentiated HER3-ADC. We look forward to nominating a development candidate this year and to the advancement of our HER3-ADC program toward the clinic, with the goal of improving patient outcomes."
Details of the poster presentation at AACR (Free AACR Whitepaper) 2024 are as follows:
Title: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers
Abstract: #3121
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates
Session Date and Time: Monday, April 8, from 1:30 p.m. to 5 p.m. PT